Infantile-onset inflammatory bowel disease in a patient with Hermansky-Pudlak syndrome: a case report
- 519 Downloads
Hermansky-Pudlak syndrome (HPS) is a rare, genetically heterogeneous disorder that manifests oculocutaneous albinism together with bleeding diatheses that reflect a platelet storage pool deficiency. Ten genetic subtypes of this autosomal recessive condition have been described to date. Some patients with Hermansky-Pudlak syndrome type 1, 4, or 6 develop Crohn’s-like inflammatory bowel disease at any age including early childhood, but most often in adolescence or young adulthood. Here we report infantile-onset of inflammatory bowel disease in a patient with Hermansky-Pudlak syndrome type 1 who responded to infliximab.
A Japanese boy, the second child of non-consanguineous healthy parents, was born with chalky white skin, silvery-white hair, and gray eyes, representing oculocutaneous albinism. He developed frequent diarrhea and fever accompanied by weight loss at 6 months, and was diagnosed with Crohn’s-like inflammatory bowel disease based on the endoscopic finding of longitudinal ulcerations in the colon and the histopathologic finding of nonspecific chronic inflammation without granulomas at the age of 11 months. Treatment with an elemental diet, salazosulfapyridine, and corticosteroids failed to improve clinical or laboratory abnormalities, and the diarrhea became bloody. At 13 months he began treatment with infliximab, which produced marked improvement followed by clinical remission. Endoscopy at 20 months demonstrated healing of the colonic mucosa. At 22 months he is in sustained clinical remission receiving only infliximab. Because albinism with inflammatory bowel disease suggested Hermansky-Pudlak syndrome, we performed genetic screening using next-generation sequencing in a targeted gene panel analysis for primary immunodeficiency disease and/or inflammatory bowel disease. The patient proved to have a compound heterozygous mutation of the HPS1 gene resulting in Hermansky-Pudlak syndrome type 1.
We consider this report to be the first account of type 1 Hermansky-Pudlak syndrome with infantile-onset of inflammatory bowel disease. Early administration of infliximab was effective. We recommend next-generation sequencing for patients with very early-onset inflammatory bowel disease suspected to be monogenic.
KeywordsHermansky-Pudlak syndrome Early-onset inflammatory bowel disease Monogenic inflammatory bowel disease Infliximab
Inflammatory bowel disease
Hermansky-Pudlak syndrome (HPS) is a rare, genetically heterogeneous disorder that manifests oculocutaneous albinism together with bleeding diatheses that reflect a platelet storage pool deficiency. Electron microscopically, lysosomes and related organelles in reticuloendothelial and other organs have shown lipofuscin accumulation [1, 2]. Ten genetic subtypes of this autosomal recessive condition have been described to date [1, 3]. Some patients with HPS, specifically those with genotype HPS-1, HPS-2, or HPS-4, are predisposed to interstitial lung disease that usually presents in mid-adulthood but rarely in late adolescence . In addition, some patients with HPS, specifically HPS-1, − 4, and − 6, develop Crohn’s-like inflammatory bowel disease (IBD). HPS with IBD can present at any age including early childhood, but most often emerges in adolescence and young adulthood [1, 2].
We report an infantile-onset IBD patient with HPS-1 who responded to infliximab (IFX).
A Japanese boy was born by spontaneous vaginal delivery at 39 weeks of gestation, with a birth weight of 2616 g. He was the second child of non-consanguineous healthy parents.
He was born with chalky white skin, silvery-white hair, and gray eyes, indicating oculocutaneous albinism. He also showed horizontal nystagmus. At 6 months of age, he developed frequent diarrhea and fever accompanied by weight loss.
Based on clinical, laboratory, and endoscopic findings, the patient was diagnosed with Crohn’s-like IBD. He was treated with an elemental diet, salazosulfapyridine, and corticosteroids, which failed to improve clinical or laboratory findings, and bloody diarrhea ensued. Given lack of improvement, he was transferred at 13 months of age to Kurume University Hospital, where he began treatment with IFX. He soon showed marked improvement, followed by clinical remission. At 20 months of age, endoscopy showed healing of the colonic mucosa (Fig. 1d). Currently, at 22 months of age, the patient is in sustained clinical remission, receiving only IFX (7 mg/kg) every 8 weeks.
Because of albinism, nystagmus, and IBD, an association suggestive of HPS, platelet morphology was evaluated. Electron microscopy showed absence of dense bodies in platelets, which was consistent with a diagnosis of HPS. Following parental informed consent, we performed genetic screening using next-generation sequencing in a targeted gene panel analysis for primary immunodeficiency disease and/or IBD including HPS1, HPS4, and HPS6 genes (Additional file 1) [1, 4]. We identified 2 heterozygous mutations in the HPS1 gene in the patient (c.398 + 5G > A and c.1323dupA) and a heterozygous mutation in each parent (father, c.398 + 5G > A; mother, 1323dupA). These mutations have been reported previously in Japanese patients with HPS-1 . We diagnosed the patient with HPS-1 resulting from compound heterozygous mutation of the HPS1 gene.
Discussion and conclusions
HPS can be caused by 10 different genotypes involving various chromosomes. These aberrant genes cause abnormal vesicle formation involving melanosomes, platelet dense bodies, and a subset of lysosomes. This results in visual impairment, skin hypopigmentation, and increased risk of bleeding [1, 3]. IBD has been reported in patients with HPS-1, − 4, and − 6; the pathogenetic mechanisms are unknown [1, 2].
IBD in HPS shows many of the same pathologic features as the more common Crohn’s colitis: irregular distribution of large bowel lesions, interspersed with regions of normal mucosal architecture; superficial crypt abscesses; and prominent inflammatory cell infiltrates in involved areas [2, 6, 7]. In a study of 122 subjects with HPS, 8% overall were found to have IBD; among those with gastrointestinal symptoms, 33% were diagnosed with IBD . IBD in HPS can present at any age including early childhood but most commonly becomes evident in adolescence and young adulthood. To our knowledge, the youngest HPS patient reported to develop IBD was 2 years old , making our patient the youngest to present with IBD and the first reported HPS patient with IBD onset during infancy.
In some patients with HPS, conventional therapy of IBD including aminosalicylates and corticosteroids has been unsuccessful. Recent reports maintain that immunosuppressants and anti-tumor necrosis factor α therapy such as IFX may be effective for IBD in patients with HPS [2, 6, 7]. Use of compounds containing 5-aminosalicylic acid is an area of controversy because of the HPS platelet storage pool defect . In fact, our patient is now in sustained clinical remission with colonic mucosal healing using only IFX.
Patients with a diverse spectrum of rare genetic disorders can present with IBD, a situation referred to as monogenic IBD [4, 8, 9]. Patients with these disorders often develop symptoms during infancy or early childhood, along with endoscopic or histologic features of Crohn’s disease, ulcerative colitis, or unclassified IBD. HPS is considered one of the monogenic IBDs [1, 2, 8]. Distinguishing monogenic forms among IBD patients under 6 years old can be crucial in determining the best treatment. Genetic screening using next-generation sequencing is a highly useful approach to diagnosis of patients with monogenic IBD [4, 8, 9]. In this patient, the clinical features of oculocutaneous albinism with nystagmus are consistent with an underlying diagnosis of HPS . Such characteristic features may aid in diagnosing specific etiologies of infantile-onset IBD. Our patient represents a case in point; we diagnosed him with HPS-1 by genetic analysis as an infant and could treat him successfully with early introduction of IFX.
In conclusion, we consider our patient to be the first known HPS-1 patient with infantile-onset of IBD. Early introduction of IFX was effective therapy. Physicians should consider genetic screening using next-generation sequencing when they treat patients with very early-onset IBD suspected to be monogenic.
The authors thank the patient and his parents for their cooperation. This work is supported by grants from Japanese Ministry of Health, Labour and Welfare (H29-013, H29-020) to YS.
This work is supported by grants from Japanese Ministry of Health, Labour and Welfare (H29–013, H29–020) to YS.
TM contributed to the concept and design of the study. JI, TM, YT1, KK, MJ, YT2, SY, HK, and YY carried out analysis and interpretation of data. TU and YS performed genetic analysis. JI and TM wrote the manuscript, which was edited by TU and YS. YY supervised the study and reviewed the manuscript. Thus, all authors contributed to the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The genetic analysis protocol was approved by the Institutional Review Board at the Ethical Committee of Tohoku University. Written informed consent was obtained from the patient’s parents for participating the study.
Consent for publication
Written informed consent was obtained from the patient’s parents for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Tatsuki Mizuochi is an Editorial Board Member for BMC Gastroenterology. Other authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.